Date: 2017-02-10
Type of information: Nomination
Compound: chief medical officer
Company: Noxxon Pharma (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 10, 2017, Noxxon Pharma has announced that Jarl Ulf Jungnelius, M.D., Ph.D. will take over the role of chief medical officer. Dr. Jungnelius, who is already familiar with the company’s programs in a consulting capacity, will now increase his involvement with Noxxon, allowing for a period of overlap with Dr. Matthias Baumann whose current contract as Chief Medical Officer expires in June 2017.
- Dr. Jungnelius’ career includes leadership positions at Celgene, Pfizer, Takeda and Eli Lilly and significant roles in the approval of several successful oncology drugs including Abraxane®, Gemzar®, Alimta® and Revlimid®. Of particular relevance to Noxxon is his prior experience in immune-oncology and his involvement with two agents that have been approved for pancreatic cancer, one of the indications pursued in the upcoming clinical trial of NOX-A12 in combination with Keytruda® which will be conducted in collaboration with Merc&Co.
Jarl Ulf Jungnelius worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He is currently chief medical officer at Vaximm, supervisory board director of Isofol Medical, Biovica International and Monocl and has been a director at Oncopeptides since April 2011. He received both a Bachelor of Science degree and his M.D. from the Karolinska Institute in Stockholm.
Financial terms:
Latest news:
Is general: Yes
